August 2015 Newsletter

August 19, 2015:

Big Three Ophthalmic Companies Report Mixed Q2-2015 Results

Figures reflect market struggles for each of the firms and the industry as a whole.

August 19, 2015:

Ultrasonic Phaco Machines Endure, Despite Ongoing Challenges from Newer Technology

The first Cavitron model 7001 was commercialized in 1970, and an estimated 200,000 ultrasonic phaco (USP) machines have been purchased since then by cataract surgeons globally.

August 19, 2015:

ESCRS Meeting is Must-See Conference for New Technology

Sessions include updates on Alcon PanOptix trifocal IOL and Abbott Symfony extended depth of focus lens.

August 19, 2015:

Razumab, the First Biosimilar to Lucentis, Enters India’s Market

The drug is priced at a 25 percent discount to the Roche/Novartis VEGF inhibitor.

August 19, 2015:

Allergan’s Battle with Valeant Dissected at US Hearing on Tax Code

David Pyott, former CEO of Allergan, and Howard Schiller, former CFO of Valeant, testified on the events that played out in 2014.

August 19, 2015:

Allergan’s Saunders Looking for Transformational Deal

Sale of generic assets to Teva for $40.5 billion gives the Dublin-based firm a cash infusion.

August 19, 2015:

US Appeals Court Upholds Allergan’s Patents on Lumigan 0.01%

Three-judge panel recognized firm’s claim that the new formulation offered unexpected properties and was sufficiently different from previous inventions.

August 19, 2015:

Restasis Faces Growing Threat from Generic Competitors, Allergan Confirms

Sales for the dry eye treatment totaled $1.08 billion in 2014.

August 19, 2015:

Inotek Closes $79.2 Million Offering; Glaucoma Drug Candidate Readies for Phase III

In July, the stock price jumped 200 percent, as the company reported late-stage plans for trabodenoson.

August 19, 2015:

Allegro Reports Phase II Results for New Pharmacologic Vitreolytic

Luminate would challenge ThromboGenics’ Jetrea, which has struggled due to lack of demand.

August 19, 2015:

Avastin Carries No Greater Risk of Endophthalmitis, Penn Study Suggests

Researchers say proposed FDA time restriction on using compounded Avastin may have unintended consequences.

August 19, 2015:

NICE backs Eylea, Ozurdex for Diabetic Macular Edema

Agency says DME affects around 189,000 people with diabetes in the UK.

August 19, 2015:

Researchers Simulate Vision Produced by Retinal Prosthesis, Optogenetics

Previous "scoreboard" model is unrealistic, the scientists said.

August 19, 2015:

Second Sight’s Argus II Used to Treat Dry AMD

The study is being conducted at Manchester Royal Eye Hospital, where surgeons hope to enroll another four patients.

August 19, 2015:

Another Mobile Eye Exam Service Launches; OD at Helm

The Opternative exam is accessed via a desktop computer and requires an android device to answer questions.

August 19, 2015:

Eylea Pulls Ahead of Lucentis in Treatment of DME

The newest VEGF inhibitor has made significant gains since Q3-2014, according to Market Scope surveys.

August 19, 2015:

Market Scope to Attend Millennial Eye Live 2015

August 19, 2015:

Glaukos’ Dual-Stent Implant Receives Approval in Australia

The device allows an ophthalmic surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point.

August 19, 2015:

Adaptica to Launch Wearable Adaptive Refractor

The company plans to roll out the VisionFit Wearable Adaptive Refractor at the 2015 ESCRS meeting in Barcelona.

August 19, 2015:

August 2015 New Briefs

Social media